Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Gasotransmitters in Modern Medicine: Promises and Challenges in the Use of Porous Crystalline Carriers

Pinto RV., Pinto ML., Serre C.

Narrative Review, published in Adv Healthc Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Healthc Mater (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40059496
PMCID
PMC12506862
DOI
10.1002/adhm.202404553
Citations
7

Abstract (original English)

Gas therapy using gasotransmitters is of exponential interest due to the growing recognition of gas signaling molecules that can be involved in multiple therapeutic actions. Finding suitable methods for delivering these molecules is crucial, and porous materials, notably metal-organic frameworks (MOFs), have shown exceptional potential as gas carriers, enabling safe and controlled local delivery. The challenges to translate these MOF therapies to clinical use require not only to validate the mechanisms of action and signaling pathways for the released gas molecules but also get a deep understanding into the MOF rational design, as it requires a combination of features to maximize the therapeutic outcomes. In this perspective, we outline the key criteria for designing suitable MOFs for gas delivery applications and highlight the expanding range of therapeutic opportunities these materials may offer. Readers can use these insights of MOF design and features to develop gasotransmitter therapies with realistic clinic interest.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansDrug CarriersPorosityGasotransmittersMetal-Organic Frameworks

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.